The FcgammaRIIa polymorphism in patients with chronic kidney graft rejection

Transplantation Proceedings
A PawlikB Gawronska-Szklarz

Abstract

The FcgammaRIIa receptors, which provide a crucial link between cellular and humoral components of the immune response, display allelic polymorphism. Individuals are homozygous for either arginine 131 (RR131) or histidine 131 (HH131) or are heterozygous for these two alleles (RH131). The HH131 genotype binds human IgG2 with high RR131 with low, and RH131 with intermediate affinity. The aim of the study was to evaluate the FcgammaRIIa polymorphism in patients with chronic kidney graft rejection. The study included 121 renal transplant recipients: 53 patients with long-term stable graft function and 68 with chronic allograft rejection. The distribution of FcgammaRIIa genotypes in patients with chronic kidney graft rejection did not differ significantly from that in patients with stable graft function. The results suggest that the FcgammaRIIa polymorphism is not an important genetic risk factor for chronic rejection of kidney allografts.

References

Jul 1, 1990·The Journal of Experimental Medicine·P A WarmerdamP J Capel
Sep 18, 1997·Transplantation Proceedings·K Solez
Jun 26, 1998·Transplant Immunology·A J Matas
Feb 13, 1999·Kidney International·L C RacusenY Yamaguchi
Mar 20, 1999·Transplantation Proceedings·P DelafontaineY Okura
Nov 27, 1999·Transplantation Proceedings·P HäyryH Savolainen
Dec 21, 2002·Transplantation Proceedings·A PawlikB Gawronska-Szklarz

❮ Previous
Next ❯

Citations

Aug 15, 2006·Advanced Drug Delivery Reviews·Leonard G Presta
Feb 27, 2018·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M L ArnoldG A Böhmig
Feb 5, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·N M ValenzuelaE F Reed
Dec 3, 2016·Current Transplantation Reports·Tomas Castro-Dopico, Menna R Clatworthy
Sep 10, 2021·Frontiers in Immunology·Markus WahrmannCaner Süsal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.